Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Patent
1997-01-07
2000-01-04
Prouty, Rebecca E.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
530300, 530324, 536 235, 435 691, 4352523, 4353201, C07K 100, C07H 2104, C12P 2106, C12N 120
Patent
active
060108800
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel mutants of the first Kunitz domain (K.sub.1) of the human lipoprotein-associated coagulation inhibitor LACI, which inhibit plasmin. The invention also relates to other modified Kunitz domains that inhibit plasmin and to other plasmin inhibitors.
2. Description of the Background Art
The agent mainly responsible for fibrinolysis is plasmin, the activated form of plasminogen. Many substances can activate plasminogen, including activated Hageman factor, streptokinase, urokinase (uPA), tissue-type plasminogen activator (tPA), and plasma kallikrein (pKA). pKA is both an activator of the zymogen form of urokinase and a direct plasminogen activator.
Plasmin is undetectable in normal circulating blood, but plasminogen, the zymogen, is present at about 3 .mu.M. An additional, unmeasured amount of plasminogen is bound to fibrin and other components of the extracellular matrix and cell surfaces. Normal blood contains the physiological inhibitor of plasmin, .alpha..sub.2 -plasmin inhibitor (.alpha..sub.2 -PI), at about 2 .mu.M. Plasmin and .alpha..sub.2 -PI form a 1:1 complex. Matrix or cell bound-plasmin is relatively inaccessible to inhibition by .alpha..sub.2 -PI. Thus, activation of plasmin can exceed the neutralizing capacity of .alpha..sub.2 -PI causing a profibrinolytic state.
Plasmin, once formed: hemostasis by causing formation of friable, easily lysed clots from the degradation products, and inhibition of platelet adhesion/aggregation by the fibrinogen degradation products; IIb/IIIa preventing adhesion to injured endothelium in areas of high shear blood flow and impairing the aggregation response needed for platelet plug formation (ADEL86); pathway further promoting a prolytic state. Robbins (ROBB87) reviewed the plasminogen-plasmin system in detail. ROBB87 and references cited therein are hereby incorporated by reference.
Fibrinolysis and Fibrinogenolysis
Inappropriate fibrinolysis and fibrinogenolysis leading to excessive bleeding is a frequent complication of surgical procedures that require extracorporeal circulation, such as cardiopulmonary bypass, and is also encountered in thrombolytic therapy and organ transplantation, particularly liver. Other clinical conditions characterized by high incidence of bleeding diathesis include liver cirrhosis, amyloidosis, acute promyelocytic leukemia, and solid tumors. Restoration of hemostasis requires infusion of plasma and/or plasma products, which risks immunological reaction and exposure to pathogens, e.g. hepatitis virus and HIV.
Very high blood loss can resist resolution even with massive infusion. When judged life-threatening, the hemorrhage is treated with antifibrinolytics such as .epsilon.-amino caproic acid (See HOOV93) (EACA), tranexamic acid, or aprotinin (NEUH89). Aprotinin is also known as Trasylol.TM. and as Bovine Pancreatic Trypsin Inhibitor (BPTI). Hereinafter, aprotinin will be referred to as "BPTI". EACA and tranexamic acid only prevent plasmin from binding fibrin by binding the kringles, thus leaving plasmin as a free protease in plasma. BPTI is a direct inhibitor of plasmin and is the most effective of these agents. Due to the potential for thrombotic complications, renal toxicity and, in the case of BPTI, immunogenicity, these agents are used with caution and usually reserved as a "last resort" (PUTT89). All three of the antifibrinolytic agents lack target specificity and affinity and interact with tissues and organs through uncharacterized metabolic pathways. The large doses required due to low affinity, side effects due to lack of specificity and potential for immune reaction and organ/tissue toxicity augment against use of these antifibrinolytics prophylactically to prevent bleeding or as a routine postoperative therapy to avoid or reduce transfusion therapy. Thus, there is a need for a safe antifibrinolytic. The essential attributes of such an agent are: immunogenicity and organ/tissue toxicity. by an efficacious antifibrinolytic are chymotrypin-homolo
REFERENCES:
patent: 4118481 (1978-10-01), Schnabel et al.
patent: 4153687 (1979-05-01), Schnabel et al.
patent: 5223409 (1993-06-01), Ladner et al.
Adelman et al., Blood, 68(6):1280-1284 (1986).
Anba et al., Biochimie, 70(6):727-733 (1988).
Auerswald et al., Bio. Chem. Hoppe-Seyler, 369(Suppl):27-35 (1988).
Baneyx & Georgiou, J. Bacteriol., 173(8):2696-2703 (1991).
Baneyx and Georgiou, J. Bacteriol., 172(1):491-494 (1990).
Browne et al., GeneBank, Accession No. M74220 (1991).
Broze et al., Biochemisty, 29(33):7539-7546 (1990).
Colman et al., Hemostasis and Thrombosis, Second Edition (Colman et al., eds; ISBN 0-397-50679-1) Chap. 1, pp. 3-17 (1987).
Dennis and Lazarus, J. Biological Chem., 269(35):22129-22136 (1994).
Dennis and Lazarus, J. Biological Chem., 269(35):22137-22144 (1994).
Eigenbrot et al., Protein Engineering, 3(7):591-598 (1990).
Ellis et al., Ann. NY Acad. Sci., 667:13-31 (1992).
Fidler and Ellis, Cell, 79:185-188 (1994).
Fraedfich et al., Thorac. Cardiovasc. Surg., 37(2):89-91 (1989).
Gardell, Toxicol. Pathol., 21(2):190-198 (1993).
Girard et al., J. Biol. Chem., 266(8):5036-5041 (1991).
Girard et al., Nature, 338:518-20 (1989).
Cregg et al., Bio/Technology, 11:905-910 (1993).
Hoover et al., Biochemistry, 32:10936-10943 (1993).
Hynes et al., Biochemistry, 29:10018-10022 (1990).
Kido et al., Biochem. & Biophys. Res. Comm., 167(2):716-721 (1990).
Kido et al., J. Biol. Chem., 263(34):18104-18107 (1988).
Kurjan and Herkowwitz, Cell, 30:933-943 (1982).
Laskowski and Kato, Ann. Rev. Biochem., 49:593-626 (1980).
Leatherbarrow and Salacinski, Biochemistry, 30(44):1071710721 (1991).
Lohmann and Marshall, Refract. Corneal. Surg. 9(4):300-302 (1993).
Lucas et al., J. Biological Chem., 258(7):4249-4256 (1983).
Mann and Lundblad, Hemostasis and Thrombosis, Second Edition (Colman et al., eds; ISBN 0-397-50679-1) Chap 10, pp. 148-161 (1987).
Miyajima et al., Gene, 37:155-161 (1985).
Neuhaus et al., Lancet, 2(8668)924-925 (1989).
Novotny et al, J. Biol. Chem., 264(31):18832-18837 (1989).
O'Reilly et al., Cell, 79:315-328 (1994).
Park and Tulinsky, Biochemistry, 25(14):3977-3982 (1986).
Putterman, Acta Chir. Scand., 155(6-7:)367 (1989).
Robbins, Hemostasis and Thrombosis, Second Edition (Colman et al., eds; ISBN 0-397-50679-1), Chap. 21, pp. 340-357 (1987).
Schechter and Berger, Biochem. Biophys. Res. Commun. 32(5):898-902 (1968).
Schechter and Berger, Biochem. Biophys. Res. Commun., 27(2):157-162 (1967).
Schnabel et al., Biol. Chem. Hoppe-Seyler, 367:1167-1176 (1986).
Sheridan et al., Dis. Colon Rectum, 32(6):505-508 (1989).
Sprecher et al., PNAS USA, 91:3353-3357 (1994).
Van Dijl et al., EMBO J., 11(8):2819-2828 (1992).
Varadi and Patthy, Biochemistry, 23(9):2108-2112 (1984).
Varadi and Patthy, Biochemistry, 22(10):2440-2446 (1983).
Vedvick et al., J. Ind. Microbiol., 7:197-201 (1991).
Wagner et al., Biochem Biophy. Res. Comm., 186:1138-1145 (1992).
Wun et al., J. Biol. Chem. 263(13):6001-6004 (1988).
Kido et al. Biochem Biophys. Res. comm. 167(2):716-721, Mar. 16, 1990.
Ladner Robert Charles
Markland William
Dyax Corp.
Prouty Rebecca E.
Saidha Tekchand
Yankwich Leon R.
Zwicker Kenneth P.
LandOfFree
Inhibitors of human plasmin derived from the kunitz domains does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of human plasmin derived from the kunitz domains, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of human plasmin derived from the kunitz domains will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1071839